March 2012
Volume 53, Issue 14
Free
ARVO Annual Meeting Abstract  |   March 2012
Novel Anti-CTGF RNAi Therapy for Treatment of Proliferative Vitreoretinopathy (PVR) and other Ocular Disorders
Author Affiliations & Notes
  • Michael J. Byrne
    Pharmacology, RXi Pharmaceuticals, Worcester, Massachusetts
  • Glenna Ford
    Pharmacology, RXi Pharmaceuticals, Worcester, Massachusetts
  • James Cardia
    Pharmacology, RXi Pharmaceuticals, Worcester, Massachusetts
  • Lakshmipathi Pandarinathan
    Pharmacology, RXi Pharmaceuticals, Worcester, Massachusetts
  • Karen Bulock
    Pharmacology, RXi Pharmaceuticals, Worcester, Massachusetts
  • Lyn Libertine
    Pharmacology, RXi Pharmaceuticals, Worcester, Massachusetts
  • Kevin Fettes
    Pharmacology, RXi Pharmaceuticals, Worcester, Massachusetts
  • Pamela Pavco
    Pharmacology, RXi Pharmaceuticals, Worcester, Massachusetts
  • Anastasia Khvorova
    Pharmacology, RXi Pharmaceuticals, Worcester, Massachusetts
  • Footnotes
    Commercial Relationships  Michael J. Byrne, RXi Pharmaceuticals (E); Glenna Ford, RXi Pharmaceuticals (C); James Cardia, RXi Pharmaceuticals (E); Lakshmipathi Pandarinathan, RXi Pharmaceuticals (E); Karen Bulock, RXi Pharmaceuticals (E); Lyn Libertine, RXi Pharmaceuticals (E); Kevin Fettes, RXi Pharmaceuticals (E); Pamela Pavco, RXi Pharmaceuticals (E); Anastasia Khvorova, RXi Pharmaceuticals (E)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 897. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Michael J. Byrne, Glenna Ford, James Cardia, Lakshmipathi Pandarinathan, Karen Bulock, Lyn Libertine, Kevin Fettes, Pamela Pavco, Anastasia Khvorova; Novel Anti-CTGF RNAi Therapy for Treatment of Proliferative Vitreoretinopathy (PVR) and other Ocular Disorders. Invest. Ophthalmol. Vis. Sci. 2012;53(14):897. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Proliferative vitreoretinopathy (PVR) remains a serious medical problem despite advances in vitreoretinal surgery. Connective tissue growth factor (CTGF) is over expressed in human PVR and is believed to play a key role in development of ocular fibrosis. We have developed a new class of stable, self-delivering RNAi compounds (sd-rxRNATM) that incorporate features of RNAi and antisense and results in spontaneous cellular uptake. Intradermal injection of one such compound, RXI-109, results in robust, dose-dependent, long-lasting reduction of CTGF in a rodent model of dermal wound healing. Silencing of CTGF also impacts myofibroblast differentiation and collagen deposition, both key markers of fibrosis. To determine if a CTGF sd-rxRNA could be used as potential therapy to reduce or inhibit the ocular fibrosis, we have carried out studies to establish mRNA silencing of CTGF in rodent retina following intravitreal injection.

Methods: : Preliminary studies of control sd-rxRNAs in the eye have resulted in a statistically significant reduction of target mRNA levels in the retina for up to 21 days. Here, 5 ul of a CTGF sd-rxRNA was administered by single intravitreal injection to Brown Norway rats. A non-targeting control (NTC), an sd-rxRNA directed against a different target or PBS was injected into the contralateral eye of each animal as a control. mRNA levels were evaluated by qPCR 48 h post injection.

Results: : Treatment with sd-rxRNA targeting CTGF resulted in a significant reduction of CTGF mRNA levels 48 h post injection relative to NTC (52%, p<0.01). The association of CTGF with VEGF has been reported to be important in retinopathy therefore, levels of VEGF mRNA were also quantified and found to be reduced (40%, p<0.05) in concert with the reduction of CTGF.

Conclusions: : Results presented show that targeting CTGF with sd-rxRNA not only reduces CTGF mRNA levels, but as a consequence also significantly reduces VEGF mRNA levels. This result, along with our previous report of specific and extended silencing of retinal genes by sd-rxRNA, supports the potential use of an anti-CTGF treatment for PVR and other retinopathies, including those resulting from neovascularization. Our next step is to test the efficacy of an anti-CTGF sd-rxRNA in an in vivo model of retinal detachment.

Keywords: proliferative vitreoretinopathy • wound healing • retinal neovascularization 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×